Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Genentech executes another round of layoffs, with 3 VPs axed
(1h)
AI use is surging across HHS, jumping 148% at the FDA in 2025, Bipartisan Policy Center data finds
(2h)
Novo reports data breach, tells clinical trial patients to 'remain vigilant'
(2h)
BioPharma Dive
Summit pulls $500M share sale a day after announcing it
(3h)
Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapy
(3h)
Novartis RNA drug acquired in $12B Avidity deal notches a trial win
(5h)
Endpoints News
Inside Makary’s ouster; Another win for Lilly’s triple-G; and more
(3w)
FDA clears Gilead's hepatitis D drug, four years after prior rejection
(3w)
GOP lawmaker asks Trump administration to curb China biotech deals
(3w)
BioSpace
Genentech R&D layoffs hit top exec who’s been with the biotech nearly 30 years
(4h)
Sky-high Parabilis, Kailera IPOs spur optimism—but only for derisked biotechs
(5h)
Takeda’s AI-designed pill bests BMS’ Sotyktu in head-to-head psoriasis trial
(5h)
STAT News
Nonprofit buys experimental cancer drug to maintain patient access
(48m)
Study highlights influence of socioeconomic status on children’s brain development
(1h)
Abridge inks deals with Nvidia and Lilly
(2h)
BioPharma Trend
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio launch ADME-One, a packaged ADME service for hit identification
(2w)
AI Won't Replace Clinical Programmers. It Will Split Them Into Two Groups.
(1mo)
Novo Nordisk and OpenAI Team Up to Integrate AI from Discovery to Supply Chain
(2mo)
Drug Channels
The Top 15 Specialty Pharmacies of 2025: PBM-Affiliated Pharmacies Dominate While Health Systems and Independents Gain Ground (rerun)
(8h)
Mapping the Vertical Integration of Insurers, PBMs, GPOs, Specialty Pharmacies, and Healthcare Services: DCI’s 2026 Update (rerun)
(1d)
The Top Pharmacy Benefit Managers of 2025: Market Share and Key Industry Developments (rerun)
(2d)
European Biotechnology Magazine
Novartis and Orionis get stuck in with new “molecular glue” R&D deal worth up to $1.4bn
(7h)
Heidelberg-based Veraxa ventures onto Nasdaq in turbulent market environment
(11h)
Scenic Biotech joins Michael J. Fox LRRK2 consortium with a novel lysosomal bet on Parkinson’s
(11h)
Drug Hunter
Locking the Sec61 Gate to Corral Disease
(4h)
linerixibat
(1d)
NVP-INE963
(2d)
Labiotech.EU
How Daiichi Sankyo aims to become a top five oncology player by 2035
(1d)
Beyond amyloid and dopamine: emerging technologies reshaping neurology
(1d)
Pharma in Spain: why global investors and innovators are moving in
(2d)
Bio IT World
Navigating the Perilous Journey from Lab to Market
(1d)
As AI Reshapes Drug Discovery the Lab Remains the Bottleneck
(2d)
Federation Plus Fine Tuning: The Push for Federated Learning Models Continues
(1w)
GEN News
Potential Cocaine Addiction Targets Identified Through Genetic Mapping in Rats
(1h)
New mRNA Delivery Platform Restores Muscle Function in DMD Models
(2h)
Fighting Antimicrobial Resistance with Biomaterials and Phages
(3h)
Cure Today
Treating Metastatic TNBC: Dr. Hope Rugo on ADCs and Personalized Therapy
(2mo)
Understanding High-Risk Essential Thrombocythemia
(2mo)
Son’s Decision to Donate Gave His Father a Second Chance
(2mo)
Contract Pharma
Harbour BioMed Adds Luisa Salter-Cid as Scientific Advisor
(21m)
PharmaEssentia Acquires Forus Therapeutics, Expanding Footprint in Canada
(59m)
Chiesi Group Acquires KalVista Pharmaceuticals for $1.9B
(4h)
Pharma Times
NICE backs daratumumab quadruplet for newly diagnosed transplant‑ineligible myeloma
(9h)
Anocca doses first patients with precision TCR‑T therapy
(10h)
Connecta launches phase 2a trial of neuroplasticity modulator
(1d)
Medcity News
Novartis RNA Med From $12B Deal Keeps Building Case to Become First Therapy for Rare Muscle Disease
(1h)
From Copilots to Clinical Judgment: The Next Phase of AI in Digital Behavioral Health
(5h)
AI Is Scaling Healthcare Costs Because the System Was Built That Way
(5h)
Chemical & Engineering News
Toxic chemicals accumulate in vapes as their juice runs low
(54m)
A new, ultrabright laser powers a cryo-EM advance 15 years in the making
(1h)
Coenzyme works as a molecular brake for labor
(1h)
The Pharma Letter
City Therapeutics
(1h)
Wegovy pill becomes first and only daily GLP-1 weight loss tablet approved in UK
(4h)
Takeda’s zasocitinib outperforms deucravacitinib in PsO
(4h)
Targeted Oncology
Ozekibart Plus Chemo Shows Promising Activity in R/R Ewing Sarcoma
(2mo)
Reduced CRS Rates Support Wider Adoption of Bispecifics in Myeloma
(2mo)
GLSI-100 Vaccine Shows <1% Annual Recurrence Rate in Phase 3 Breast Cancer Trial
(2mo)
MedWatch
US employers are considering dropping coverage for GLP-1 medications in 2027
(7h)
EU court urged to prioritize vaccine contract transparency over corporate interests
(7h)
EU’s new medicines act strikes a difficult balance
(8h)
In The Pipeline
Hydroxyl Radicals In Water Droplets? Doesn't Look Like It.
(2h)
A New Antibiotic Idea From An Old Source
(1d)
Insights Into Idiopathic Pulmonary Fibrosis
(2d)
Pharmaphorum
UK approves Novo Nordisk's Wegovy pill
(2h)
Takeda's TYK2 drug bests BMS's Sotyktu in psoriasis contest
(3h)
J&J adds rare disease wAIHA to Imaavy's potential uses
(6h)
Drug Discovery Weekly
DaltonTx launches AI drug discovery platform
(5h)
Webinar – The orchestrated lab: Moving beyond siloed automation
(8h)
Bead BioPharma emerges from stealth with novel drug platform
(8h)
HIT Consultant
Why Validation is Becoming the Proving Ground for AI in Life Sciences
(4h)
Med-Metrix Acquires CanAide to Automate Patient Access
(5h)
Surgical AI Startup Uncovr Emerges from Stealth with $7M Seed Funding
(6h)
Insights: Pink Sheet
UK’s HRA Maps Path To Regulatory Clarity For AI-Enabled Trials
(4h)
US-Approved Drugs Otarmeni, Idvynso And Unloxcyt Filed In EU
(6h)
Asundexian, Venglustat And Japanese Encephalitis Vaccine Among Latest EU Filings
(6h)
BioXconomy
New study reveals $35 as tipping point for prescription abandonment
(1h)
Japan urged to regulate generative AI in clinical trials
(2h)
Dodging the cytokine storm: Delivering ASOs without adverse effects
(5h)
BioCentury
Pinnacle: Designing oral peptides to close the gap with injectable biologics
(19h)
Moving faster at the academia-industry interface — a BioCentury podcast
(20h)
LRRK2 inhibitor failure pushes Parkinson’s field toward genetic enrichment
(20h)
SCRIP
ADA 2026: Roche Still Looking For Ways To Stand Out In Obesity
(3h)
Executives On The Move: Four CEOs And Five CFOs Among This Week’s Changes
(5h)
US Drug Shortages Ease But Discontinuations Surge, Asia Supply Chain Risks Run Deep
(6h)